What's new?: The 2010 WHO classification for tumours of the pancreas

被引：28

作者：

Lüttges J. ^{[1
]}

机构：

[1] Institut für Pathologie, Klinikum Saarbrücken, Saarbrücken 66119

来源：

Der Pathologe | 2011年 / 32卷 / Suppl 2期

关键词：

Carcinoma; pancreatic ductal; Neuroendocrine carcinoma; Neuroendocrine tumors; Pancreatic neoplasms; Precursor lesion;

D O I：

10.1007/s00292-011-1515-2

中图分类号：

学科分类号：

摘要：

The new WHO classification of tumours of the pancreas logically includes both exocrine and neuroendocrine neoplasms in one volume, thus differing from all previous editions. Ductal adenocarcinoma is still the most frequent and clinically the most relevant malignant tumour. Its subtypes and variants are described in detail, as are mixed tumours. Other ductal tumours [mucinous cystic neoplasms (MCN) and intraductal papillary mucinous neoplasms (IPNM)] are classified as neoplasms with various grades of dysplasia up to invasive carcinoma. A new subtype of IPNM, intraductal tubulopapillary neoplasm (ITPN), has been characterized and newly added to the IPMN group. Serous and acinar tumours are classified as neoplasms with varying grades of dysplasia. Solid pseudopapillary neoplasm (SPN) is regarded as malignant (low grade) as a matter of principle because of its inherent potential to metastasize. Neuroendocrine neoplasms are characterized as G1 or G2 neuroendocrine tumours (NET) and neuroendocrine carcinomas (NEC, highly malignant). Syndromatic NETs are described and named according to their hormone expression pattern. The problems of staging when applying either the TNM or AJCC/UICC (American Joint Committee on Cancer/Union Internationale Contre le Cancer) classifications, which apply equally to endocrine and exocrine tumors, are discussed. © 2011 Springer-Verlag.

引用

页码：332 / 336

页数：4

共 14 条

[1]

Abraham S.C., Klimstra D.S., Wilentz R.E., Yeo C.J., Conlon K., Brennan M., Cameron J.L., Wu T.-T., Hruban R.H., Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations, American Journal of Pathology, 160, 4, pp. 1361-1369, (2002)

[2]

Brune K., Abe T., Canto M., O'Malley L., Klein A.P., Maitra A., Volkan Adsay N., Fishman E.K., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H., Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer, American Journal of Surgical Pathology, 30, 9, pp. 1067-1076, (2006)

[3]

Canto M.I., Goggins M., Hruban R.H., Petersen G.M., Giardiello F.M., Yeo C., Fishman E.K., Brune K., Axilbund J., Griffin C., Ali S., Richman J., Jagannath S., Kantsevoy S.V., Kalloo A.N., Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study, Clinical Gastroenterology and Hepatology, 4, 6, pp. 766-781, (2006)

[4]

Chari S.T., Takahashi N., Levy M.J., Et al., A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer, Clin Gastroenterol Hepatol, 7, pp. 1097-1103, (2009)

[5]

Delellis R.A., Lloyd R.V., Heitz P.U., Et al., Pathology and Genetics of Tumours of Endocrine Organs, (2004)

[6]

Klimstra D.S., Modlin I.M., Adsay N.V., Et al., Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set, Am J Surg Pathol, 34, pp. 300-313, (2010)

[7]

Kloppel G., Couvelard A., Perren A., Et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification, Neuroendocrinology, 90, pp. 162-166, (2009)

[8]

Lowenfels A.B., Maisonneuve P., DiMagno E.P., Elitsur Y., Gates Jr. L.K., Perrault J., Whitcomb D.C., Hereditary pancreatitis and the risk of pancreatic cancer, Journal of the National Cancer Institute, 89, 6, pp. 442-446, (1997)

[9]

Rindi G., Kloppel G., Couvelard A., Komminoth P., Korner M., Lopes J.M., McNicol A.-M., Nilsson O., Perren A., Scarpa A., Scoazec J.-Y., Wiedenmann B., TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system, Virchows Archiv, 451, 4, pp. 757-762, (2007)

[10]

Scarpa A., Mantovani W., Capelli P., Et al., Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients, Mod Pathol, 23, pp. 824-833, (2010)

← 1 2 →